Reproductive Endocrinology Practice Questions

Q: Regarding androgen insensitivity syndrome, which of the following statements is/are true?

Scanty pubic hair. **Explanation:** Androgen Insensitivity Syndrome (AIS), formerly known as Testicular Feminization Syndrome, is an X-linked recessive condition where there is a functional defect in the androgen receptor. **1. Why "Scanty pubic hair" is correct:** In AIS, individuals have high levels of circulating testosterone (produced by the undescended testes), but the body’s receptors cannot respond to it. Since the development of pubic and axillary hair is dependent on androgen action, these patients typically present with **absent or scanty pubic and axillary hair**. This is a hallmark clinical sign that differentiates AIS from Mullerian Agenesis (MRKH), where hair growth is normal. **2. Why other options are incorrect:** * **Option A (Genotype is 46,XX):** Incorrect. The genotype is **46,XY**. These are phenotypically female individuals who are genetically male. * **Option C (Well-developed female external genitalia):** While the external genitalia appear female (due to peripheral conversion of testosterone to estrogen), they are often described as "blind-ending" or having a **shortened vagina**. The labia may be underdeveloped, and the clitoris is usually small. * **Option D (Uterus is present):** Incorrect. The testes produce **Anti-Mullerian Hormone (AMH)**, which causes regression of the Mullerian ducts. Therefore, the uterus, fallopian tubes, and upper third of the vagina are **absent**. **NEET-PG High-Yield Pearls:** * **Presentation:** Primary amenorrhea with excellent breast development (due to aromatization of androgens to estrogen). * **Gonads:** Undescended testes are present (often in the inguinal canal or abdomen) and must be removed after puberty to prevent **gonadoblastoma/dysgerminoma**. * **Differential Diagnosis:** In **MRKH (Mullerian Agenesis)**, the genotype is 46,XX, ovaries are present, and pubic hair is normal. In **AIS**, the genotype is 46,XY, testes are present, and pubic hair is scanty.

Q: A 28-year-old lady is suspected to have polycystic ovarian disease. For testing LH and FSH, which days of the menstrual cycle are best for sample collection?

Days 2-5. **Explanation:** The correct answer is **A. Days 2-5**. **1. Why Days 2-5 is correct:** In reproductive endocrinology, testing for LH (Luteinizing Hormone) and FSH (Follicle Stimulating Hormone) must be done during the **early follicular phase** (Days 2-5 of the menstrual cycle). At this stage, the ovaries are in a "quiescent" state with minimal feedback from estrogen and progesterone. This provides a **baseline measurement** of pituitary function. In PCOS, this timing is crucial to identify the characteristic **reversal of the LH:FSH ratio** (typically >2:1 or 3:1), as LH levels are inappropriately elevated while FSH remains low-normal. **2. Why other options are incorrect:** * **Day 10 (Option B):** This is the mid-follicular phase. Dominant follicle selection has already occurred, and rising estrogen levels begin to suppress FSH and stimulate LH, making baseline assessment inaccurate. * **Days 13-15 (Option C):** This corresponds to the **periovulatory period**. There is a physiological LH surge and a smaller FSH surge to trigger ovulation. Testing here would show high LH levels in any healthy woman, making it impossible to diagnose PCOS. * **Days 24-26 (Option D):** This is the **late luteal phase**. High levels of progesterone from the corpus luteum suppress both LH and FSH, rendering the test results clinically useless for baseline evaluation. **Clinical Pearls for NEET-PG:** * **Rotterdam Criteria:** Diagnosis of PCOS requires 2 out of 3: (1) Hyperandrogenism, (2) Oligo/anovulation, (3) Polycystic ovaries on USG. * **Gold Standard Timing:** While the LH:FSH ratio is a classic teaching point, it is no longer a mandatory diagnostic criterion under Rotterdam; however, it remains a high-yield exam fact. * **AMH (Anti-Müllerian Hormone):** Often elevated in PCOS and can be tested on *any* day of the cycle, unlike LH/FSH.

Q: A patient with spontaneous abortion presents with a history of amenorrhea and an FSH level of 6 IU/mL. What is the most likely diagnosis?

Uterine synechiae. **Explanation:** The clinical presentation of amenorrhea following a spontaneous abortion (which often involves a D&C procedure) combined with a **normal FSH level (6 IU/mL)** strongly points towards an anatomical cause rather than a hormonal one. **1. Why Uterine Synechiae is correct:** Uterine synechiae, or **Asherman Syndrome**, is the most common cause of secondary amenorrhea following intrauterine instrumentation (like curettage for abortion). The normal FSH level indicates that the Hypothalamic-Pituitary-Ovarian (HPO) axis is intact and functioning correctly. The amenorrhea is "outflow tract" related; the endometrium has been replaced by adhesions, making it unresponsive to hormonal stimulation. **2. Why other options are incorrect:** * **Ovarian Failure:** This would present with **Hypergonadotropic Hypogonadism**. You would expect a significantly elevated FSH (>25–40 IU/mL) due to the lack of negative feedback from estrogen. * **Pituitary Failure:** This would present with **Hypogonadotropic Hypogonadism**. You would expect very low or undetectable levels of FSH and LH. * **Pregnancy:** While pregnancy causes amenorrhea and a low/normal FSH, the question specifies the patient *had* a spontaneous abortion. If she were currently pregnant, the beta-hCG would be elevated, but "Uterine synechiae" is the classic "post-procedure" diagnosis tested in this context. **NEET-PG High-Yield Pearls:** * **Asherman Syndrome** is the most common cause of secondary amenorrhea where the Progesterone Challenge Test is **negative**. * **Gold Standard Investigation:** Hysteroscopy (both for diagnosis and adhesiolysis). * **Normal FSH Range:** 5–10 IU/mL. Always check FSH to differentiate between central (pituitary/hypothalamus), peripheral (ovarian), or anatomical (uterine) causes of amenorrhea.

Q: What is the most common cause of heterosexual development in a female at the expected age of puberty?

Polycystic ovarian syndrome. **Explanation:** The question asks for the most common cause of **heterosexual development** (virilization or signs of masculinization) in a female at the **expected age of puberty**. **1. Why Polycystic Ovarian Syndrome (PCOS) is correct:** PCOS is the most common endocrinopathy in women of reproductive age. While it typically presents post-menarche, it frequently manifests during the peripubertal period with signs of hyperandrogenism such as hirsutism, acne, and irregular cycles. Because of its high prevalence (5–10% of the female population), it remains the most common cause of heterosexual pubertal development compared to rarer genetic or enzymatic disorders. **2. Why the other options are incorrect:** * **Congenital Adrenal Hyperplasia (CAH):** While a major cause of virilization, the *classical* form presents at birth with ambiguous genitalia. The *non-classical* (late-onset) form can present at puberty, but its prevalence is significantly lower than PCOS. * **Pure Gonadal Dysgenesis (46,XX or 46,XY/Swyer):** This typically presents with **sexual infantilism** (failure of pubertal development) and primary amenorrhea due to streak gonads and lack of estrogen, not virilization. * **Complete Androgen Insensitivity Syndrome (CAIS):** These individuals are genotypically male (46,XY) but phenotypically female. They present with primary amenorrhea and a "hyper-feminized" appearance (large breasts, absent pubic hair) due to androgen resistance, not heterosexual development. **Clinical Pearls for NEET-PG:** * **Most common cause of ambiguous genitalia in a newborn:** CAH (21-hydroxylase deficiency). * **Most common cause of primary amenorrhea with absent uterus:** MRKH Syndrome (46,XX) or CAIS (46,XY). * **Key PCOS Diagnostic Criteria (Rotterdam):** 1. Hyperandrogenism, 2. Oligo/anovulation, 3. Polycystic ovaries on ultrasound (2 out of 3 required).

Q: Which hormone is decreased in Polycystic Ovarian Disease (PCOD)?

Progesterone. **Explanation:** In **Polycystic Ovarian Disease (PCOD/PCOS)**, the fundamental pathophysiology is **chronic anovulation**. Under normal physiological conditions, progesterone is produced by the **corpus luteum** following ovulation. Since patients with PCOD fail to ovulate regularly, the corpus luteum does not form, leading to a state of **progesterone deficiency**. This results in "unopposed estrogen" action on the endometrium, increasing the risk of endometrial hyperplasia and dysfunctional uterine bleeding. **Analysis of Options:** * **A. Androgens (Increased):** Hyperandrogenism is a hallmark of PCOD. Excessive LH stimulation of ovarian theca cells leads to increased production of testosterone and androstenedione, causing hirsutism and acne. * **C. Estrone (Increased):** While estradiol levels may be normal or slightly low, **Estrone (E1)** is significantly elevated. This occurs due to the peripheral conversion of excess androgens into estrone within adipose tissue. * **D. Insulin (Increased):** Peripheral insulin resistance is a key feature of PCOD. This leads to **compensatory hyperinsulinemia**, which further stimulates the ovaries to produce more androgens and decreases Sex Hormone Binding Globulin (SHBG) levels. **NEET-PG High-Yield Pearls:** * **LH:FSH Ratio:** Classically elevated to **>2:1 or 3:1** (due to increased GnRH pulse frequency). * **SHBG:** Decreased in PCOD, leading to higher levels of "free" (biologically active) testosterone. * **Gold Standard for Diagnosis:** Rotterdam Criteria (requires 2 out of 3: Oligo/anovulation, Hyperandrogenism, and Polycystic ovaries on ultrasound). * **Long-term Risk:** Increased risk of **Endometrial Carcinoma** due to chronic unopposed estrogen.

Q: Which of the following is NOT typically associated with Polycystic Ovary Syndrome?

Hypertension. **Explanation:** Polycystic Ovary Syndrome (PCOS) is primarily a metabolic and endocrine disorder characterized by hyperandrogenism, insulin resistance, and ovulatory dysfunction. While PCOS is a significant risk factor for developing metabolic syndrome, **Hypertension (Option A)** is not a diagnostic feature or a typical direct association of the syndrome itself. While long-term metabolic complications may eventually lead to cardiovascular issues, hypertension is not considered a hallmark of PCOS in the same way as the other options. **Why the other options are incorrect:** * **Diabetes Mellitus (Option B):** Insulin resistance is a core pathophysiological mechanism in PCOS. This leads to compensatory hyperinsulinemia, significantly increasing the risk of Impaired Glucose Tolerance and Type 2 Diabetes Mellitus. * **Obesity (Option C):** Approximately 50-80% of women with PCOS are obese. Adipose tissue exacerbates insulin resistance and contributes to the peripheral conversion of androgens to estrogens, worsening the hormonal imbalance. * **Hirsutism (Option D):** This is a clinical manifestation of hyperandrogenism (excessive terminal hair growth in a male-pattern distribution). It is one of the three criteria in the **Rotterdam Criteria** used to diagnose PCOS. **NEET-PG High-Yield Pearls:** * **Rotterdam Criteria (2 out of 3):** 1. Oligo/Anovulation, 2. Clinical/Biochemical Hyperandrogenism, 3. Polycystic ovaries on Ultrasound (≥12 follicles or volume >10cc). * **LH:FSH Ratio:** Classically elevated (3:1), though no longer a diagnostic requirement. * **Gold Standard Treatment for Infertility:** Letrozole (Aromatase inhibitor) is now preferred over Clomiphene Citrate. * **Hirsutism Scoring:** Modified Ferriman-Gallwey score (Score ≥8 is significant in Indians).

Q: What is the primary source of progesterone during a normal menstrual cycle?

Corpus luteum. **Explanation:** The correct answer is **A. Corpus luteum.** **1. Why the Corpus Luteum is correct:** During the luteal phase of the menstrual cycle, following ovulation, the remnants of the Graafian follicle undergo a process called **luteinization**. Under the influence of Luteinizing Hormone (LH), the granulosa and theca cells transform into the corpus luteum. This temporary endocrine structure becomes the primary factory for **progesterone** production. Progesterone is essential for preparing the endometrium for implantation (secretory phase) and maintaining early pregnancy until the placenta takes over (luteal-placental shift). **2. Why other options are incorrect:** * **Ovarian stroma:** This consists of connective tissue, blood vessels, and interstitial cells. While the stroma produces small amounts of androgens (like androstenedione), it is not the primary source of progesterone. * **Surface epithelium:** This is a single layer of cuboidal cells covering the ovary. Its primary role is structural and regenerative; it does not have an endocrine function related to progesterone secretion. **3. NEET-PG High-Yield Pearls:** * **Peak Progesterone:** Progesterone levels peak approximately **7 days after ovulation** (Day 21 of a 28-day cycle). * **The Luteal-Placental Shift:** The corpus luteum is the sole source of progesterone for the first **7–9 weeks** of pregnancy. After this, the placenta (syncytiotrophoblast) takes over. * **Hormonal Trigger:** LH is the primary hormone that maintains the corpus luteum in a non-pregnant cycle, while **hCG** (human Chorionic Gonadotropin) rescues it if fertilization occurs. * **Diagnostic Value:** A serum progesterone level >3 ng/mL is often used as biochemical evidence that ovulation has occurred.

Q: GnRH analogues are useful in all of the following conditions except:

Hyperprolactinemia. **Explanation:** GnRH (Gonadotropin-Releasing Hormone) analogues work by initially stimulating and then paradoxically down-regulating the pituitary GnRH receptors. This leads to a state of **hypogonadotropic hypogonadism** (pseudomenopause), which is the therapeutic goal in estrogen-dependent conditions. **Why Hyperprolactinemia is the Correct Answer:** Hyperprolactinemia is primarily managed with **Dopamine agonists** (e.g., Cabergoline, Bromocriptine). Dopamine acts as the natural prolactin-inhibiting factor. GnRH analogues have no physiological role in suppressing prolactin secretion; in fact, hyperprolactinemia itself causes infertility by suppressing GnRH pulsatility. **Analysis of Other Options:** * **Endometriosis:** GnRH analogues are a gold-standard medical treatment. By inducing a hypoestrogenic state, they cause atrophy of ectopic endometrial tissue and provide symptomatic relief from pelvic pain. * **Precocious Puberty:** In Central Precocious Puberty, continuous GnRH analogues are used to desensitize the pituitary, stopping the premature secretion of LH/FSH and preventing early epiphyseal closure (preserving adult height). * **Menstrual Disturbances:** They are used to manage heavy menstrual bleeding in conditions like **Uterine Fibroids** (to shrink the tumor before surgery) and **Dysfunctional Uterine Bleeding (DUB)** refractory to other medical therapies. **NEET-PG High-Yield Pearls:** * **Flare Effect:** Initial administration causes a transient rise in gonadotropins. To prevent this in conditions like prostate cancer, anti-androgens are co-administered. * **Add-back Therapy:** To prevent bone mineral density loss and vasomotor symptoms during long-term GnRH analogue use (usually >6 months), low-dose estrogen/progesterone is "added back." * **Other Uses:** IVF (to prevent premature LH surge), Polycystic Ovary Syndrome (PCOS), and thinning the endometrium before hysteroscopic resection.

Question 1

Regarding androgen insensitivity syndrome, which of the following statements is/are true?

Accepted Answer

Scanty pubic hair

Answer

Genotype is 46,XX

Answer

Well-developed female external genitalia

Answer

Uterus is present

Question 2

A baby girl presents with bilateral inguinal masses, which are found to be testes in the inguinal canals. Which karyotype would you expect to find in the child?

Accepted Answer

46, XY

Answer

46, XX

Answer

47, XXY

Answer

47, XYY

Question 3

A 28-year-old lady is suspected to have polycystic ovarian disease. For testing LH and FSH, which days of the menstrual cycle are best for sample collection?

Accepted Answer

Days 2-5

Answer

Day 10

Answer

Days 13-15

Answer

Days 24-26

Question 4

A patient with spontaneous abortion presents with a history of amenorrhea and an FSH level of 6 IU/mL. What is the most likely diagnosis?

Accepted Answer

Uterine synechiae

Answer

Ovarian failure

Answer

Pregnancy

Answer

Pituitary failure

Question 5

What is the most common cause of heterosexual development in a female at the expected age of puberty?

Accepted Answer

Polycystic ovarian syndrome

Answer

Congenital Adrenal hyperplasia

Answer

Pure gonadal dysgenesis

Answer

Complete androgen insensitivity syndrome

Question 6

Hypergonadotropic hypogonadism is seen in all EXCEPT?

Accepted Answer

Down syndrome

Answer

Turner syndrome

Answer

Klinefelter syndrome

Answer

Swyer's syndrome

Question 7

Which hormone is decreased in Polycystic Ovarian Disease (PCOD)?

Accepted Answer

Progesterone

Answer

Androgens

Answer

Estrone

Answer

Insulin

Question 8

Which of the following is NOT typically associated with Polycystic Ovary Syndrome?

Accepted Answer

Hypertension

Answer

Diabetes Mellitus

Answer

Obesity

Answer

Hirsutism

Question 9

What is the primary source of progesterone during a normal menstrual cycle?

Accepted Answer

Corpus luteum

Answer

Ovarian stroma

Answer

Surface epithelium of the ovary

Answer

None of the above

Question 10

GnRH analogues are useful in all of the following conditions except:

Accepted Answer

Hyperprolactinemia

Answer

Endometriosis

Answer

Precocious puberty

Answer

Menstrual disturbances

Reproductive Endocrinology — MCQs

Reproductive Endocrinology — MCQs

On this page

Practice by Chapter

Want unlimited practice?